JPMorgan raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $30 from $26 and keeps an Overweight rating on the shares. The firm sees the recent ruling from the U.S. District Court for the District of Delaware in favor of Acadia regarding its formulation patent for Nuplazid on both infringement and validity arguments against Aurobindo Pharma and other generic filers as a “clear positive.” The patent provides protection for the Nuplazid 34mg capsule formulation into 2038, the analyst tells investors in a research note. JPMorgan believes it is logical to assume the parties would appeal the ruling, a process that could take up to two years from start to finish.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $23 from $18 at BofA
- Acadia Pharmaceuticals Holds 2025 Annual Stockholder Meeting
- UnitedHealth downgraded, Home Depot upgraded: Wall Street’s top analyst calls
- Deutsche upgrades Acadia to Buy on new ‘valuation floor’
- ACADIA Pharmaceuticals Wins Favorable Patent Court Ruling
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue